SCHEMBL21189258

SCHEMBL21189258

COC(=O)N[C@H]1CCOc2c1ccc(Cl)c2C(=O)Nc1ccc(F)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.40
MEN1 O00255 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KMT2A Q03164 2/20 0.40
GLA P06280 1/20 0.40
MAOB P27338 2/20 0.39
NPC1 O15118 7/20 0.39
RAB9A P51151 7/20 0.39
MAPT P10636 2/20 0.39
TP53 P04637 1/20 0.38
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
ENPP2 Q13822 1/20 0.37
LMNA P02545 2/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21189268 0.92 RAB9A (0.42) SMN1; SMN2ALDH1A1MAOBNPC1RAB9A
SCHEMBL21189237 0.92 RAB9A (0.42) SMN1; SMN2ALDH1A1MAOBNPC1RAB9A
SCHEMBL21189535 0.90 MEN1 (0.44) SMN1; SMN2MEN1ALDH1A1KMT2AGLA
SCHEMBL21189257 0.90 MEN1 (0.44) SMN1; SMN2MEN1ALDH1A1KMT2AGLA
SCHEMBL19973417 0.89 MAOB (0.41) SMN1; SMN2MEN1ALDH1A1KMT2AGLA
SCHEMBL19973416 0.89 MAOB (0.41) SMN1; SMN2MEN1ALDH1A1KMT2AGLA
SCHEMBL19973649 0.89 TRPV1 (0.40) SMN1; SMN2MEN1ALDH1A1KMT2AMAOB
SCHEMBL19973647 0.89 TRPV1 (0.40) SMN1; SMN2MEN1ALDH1A1KMT2AMAOB
SCHEMBL21189262 0.85 TP53 (0.42) SMN1; SMN2ALDH1A1MAOBNPC1RAB9A
SCHEMBL21189485 0.85 TP53 (0.42) SMN1; SMN2ALDH1A1MAOBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2021-05-11 US disclosed
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2019-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225593-A1 SUBSTITUTED CHROMANE-8-CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF, AND METHODS USING SAME CBX8, HAVCR2, HCCS SMN1; SMN2 3837/4885MEN1 1933/4885ALDH1A1 3241/4885
US-11001564-B2 Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same CBX8, HAVCR2, HCCS SMN1; SMN2 3837/4885MEN1 1933/4885ALDH1A1 3241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.